NattoPharma Strengthens Management with New CEO
OSLO, NORWAY (August 28, 2012) -- NattoPharma ASA, the worldwide innovator of MenaQ7, a proprietary and patented vitamin K2 menaquinone-7 derived from natto, has announced a key management position: Hogne Vik, MD, PhD, MBA is the new CEO as selected by the Board of Directors of Nattopharma.
Frode M. Bohan, Executive Chairman of the Board for Nattopharma, said, “Dr Vik has previous experience at similar companies to NattoPharma, and these companies have successfully implemented development strategies and have created significant shareholder value. Dr. Vik has held key positions at Nycomed/Amersham, Natural, Pronova BioPharma and recentlyAker BioMarine Antarctic. This means that for the first time NattoPharma has a CEO that has experience in implementing strategic change and the exact executive Nattopharma currently requires."
Dr. Hogne Vik is a physician by education and has a long and successful track record in both the pharmaceutical and dietary supplement industries. As global VP in product development in Nycomed/Nycomed Amersham Dr. Vik was one of the main forces behind the development and market entrance of VisiPaque, a truly world-dominating X-ray contrast agent that remains a top-selling pharmaceutical compound in the US. Following Nycomed, Vik was instrumental in bringing Tonalin (CLA) to the European and US market, as part of Natural ASA.
Additionally, he was one of the key executives in the management team of Pronova BioPharma securing the US and Japanese market entrance of Omacor/Lovaza (the only omega-3 substance with a status as a prescription drug), which became another blockbuster drug in the US. Most recently, Dr. Vik has been the driving force behind the documentation program securing the current marketing position of Superba Krill Oil developed and manufactured by Aker BioMarine Antarctic.
Bohan added, "Dr. Vik has demonstrated managerial abilities to achieve results within the dietary supplement and pharmaceutical industries. We welcome him in the driving seat to secure the further development of NattoPharma."
About NattoPharma ASA
NattoPharma ASA, Norway is the exclusive international supplier of MenaQ7, the natural vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the marketplace for functional food and health food supplements. For more information, visit nattopharma.com.
About MenaQ7
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending. Visit menaq7.com for more information.
For more information, please contact
Camilla Lindberg
Phone nr. +47 909 54 793
Camilla@nattopharma.com
Tags: